Prostamax (KEDP) is studied in vitro as a prostate-tissue-directed short-peptide probe, used to examine how a minimal defined peptide signal influences transcriptional, proteomic and proliferation/apoptosis endpoints in prostate-derived cell populations.
Peptides of this class are proposed to act at the chromatin level to modulate tissue-specific gene-expression patterns in experimental models. It is used as a comparator/tool compound for tissue-specificity studies; observed effects depend on concentration, model system and exposure conditions.
Applications in Research
- In-vitro investigation of prostate-derived cell proliferation / apoptosis markers
- Tissue-specificity comparison across related short peptides
- Probe for short-peptide transcriptional regulation in genitourinary tissue
Specifications Summary
| Parameter |
Typical Value / Range |
| Purity (HPLC) |
≥ 99% |
| Appearance |
White to off-white lyophilised powder |
| Molecular Weight |
487.51 g/mol |
| Peptide Type |
Synthetic tetrapeptide |
| Solubility |
Water, buffered aqueous solutions |
| Storage |
–20 °C, desiccated, dark |
| Pack Size |
20 mg (total) |
Precautions & Notes
- Experimental behaviour is dependent on concentration, model system and exposure conditions
- Appropriate experimental controls are recommended
- Prolonged exposure to light, elevated temperature or aqueous environments may reduce stability
- Intended strictly for laboratory research use; not for human or veterinary application
References
Khavinson VKh, Popovich IG, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053.
https://www.mdpi.com/1420-3049/26/22/7053
Keywords: Prostamax, KEDP, short peptide, synthetic tetrapeptide
